12:00 AM
Jun 15, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Status

ANA773: Phase I halted

Anadys suspended development of ANA773 to treat cancer, which was in Phase I testing, and said it will suspend development of the compound for HCV once dosing is completed in...

Read the full 126 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >